05 May 2025 | Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma | Press Release |  |
13 Feb 2025 | February 2025 Update | Corporate Update |  |
09 Dec 2024 | Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma | Press Release |  |
19 Nov 2024 | Corporate Presentation November 2024 Update | Corporate Update |  |
13 Nov 2024 | November 2024 Update | Corporate Update |  |
05 Nov 2024 | Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting | Press Release |  |
30 Sept 2024 | IGI Announces CRADA with National Cancer Institute to Test Proprietary Oral Cbl/b Inhibitor Treatment in Triple Negative Breast Cancer | Press Release |  |
11 Sept 2024 | IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma | Press Release |  |
13 Aug 2024 | August 2024 Update | Corporate Update |  |
23 May 2024 | May 2024 Update | Corporate Update |  |
30 April 2024 | Corporate Presentation April 2024 | Corporate Update |  |
07 April 2024 | IGI presents preclinical data for ISB 2001 at AACR 2024 | Press Release |  |
08 March 2024 | Ichnos Glenmark Innovation reports the publication in Nature Communications of the preclinical development of ISB 1442 bispecific antibody for Treatment of Relapsed/Refractory Multiple Myeloma | Press Release |  |
13 February 2024 | February 2024 Update | Corporate Update |  |
30 Jan 2024 | Ichnos and Glenmark take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance - ‘Ichnos Glenmark Innovation’ | Press Release |  |
12 Dec 2023 | Ichnos Sciences Delivers Strong Evidence for its Trio of Oncology Assets at ASH 2023 Annual Meetings | Press Release |  |
06 Dec 2023 | Ichnos Sciences Appoints President and CEO Cyril Konto as Executive Director to the Board | Corporate Update |  |
09 Nov 2023 | November 2023 Update
| Corporate Update |  |
09 Nov 2023 | Ichnos Sciences Data Selected For Presentation at the 65th ASH Annual Meeting | Press Release |  |
02 Nov 2023 | Ichnos Sciences Announces Initiation of First-In-Human Clinical Trial for ISB 2001
| Press Release |  |
11 Oct 2023 | Ichnos Sciences Enters Licensing Agreement For OX40 Antagonist Monoclonal Antibody Portfolio With Astria Therapeutics | Press Release |  |
10 Aug 2023 | August 2003 Update
| Corporate Update |  |
07 Jul 2023 | Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Trispecific Antibody, ISB 2001
| Press Release |  |
18 May 2023 | May 2023 Update
| Corporate Update |  |
20 Mar 2023 | Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442
| Press Release |  |
09 Feb 2023 | February 2023 Update
| Corporate Update |  |
12 Dec 2022 | Ichnos Sciences Presents Data Supporting Three Oncology Assets at ASH 2022 Annual Meeting
| Press Release |  |
10 Nov 2022 | November 2022 Update
| Corporate Update |  |
03 Nov 2022 | Ichnos Sciences Data Selected for Presentation at the 64th ASH Annual Meeting
| Press Release |  |
09 Aug 2022 | August 2022 Update
| Corporate Update |  |
08 Jun 2022 | Webcast: Ichnos Sciences Presentation at the 2022 Jefferies Healthcare Conference
| Event |  |
26 May 2022 | August 2022 Update
| Corporate Update |  |
12 May 2022 | Pharma Boardroom: Cyril Konto, President & CEO – Ichnos Sciences | Media |  |
27 April 2022 | Law360: Ichnos Sciences’ New GC On Carving Out ‘Creative Time' | Media |  |
12 April 2022 | Genetic Engineering & Biotechnology News: Multi-Specific Ab Analytical Strategies
| Media |  |
23 Mar 2022 | Ichnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting
| Press Release |  |
18 Mar 2022 | Ichnos Sciences Presents Preclinical Data Package on First-in-class Oncology Treatment, ISB 1442, at IO360 Conference
| Press Release |  |
10 Feb 2022 | February 2022 Update
| Corporate Update |  |
16 Dec 2021
| Scrip: Ichnos Gets Going with Almirall Deal, Multiple Myeloma Bispecifics Add Sheen
| Media |  |
14 Dec 2021 | Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class IL-1RAP Antagonist Monoclonal Antibody
| Press Release |  |
11 Dec 2021 | ISB 1442 Preclinical Data Summary: First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for Relapsed / Refractory Multiple Myeloma
| Data Presentation |  |
11 Dec 2021 | Ichnos Sciences Presents Preclinical Data On Novel ISB 1442 In Relapsed/Refractory Multiple Myeloma At The ASH 2021 Annual Meeting
| Press Release |  |
11 Nov 2021 | November 2021 Update
| Corporate Update |  |
12 Aug 2021 | August 2021 Update
| Corporate Update |  |
06 Aug 2021 | Ichnos Sciences Nominates Innate Modulator ISB 1442 as Next Clinical Candidate for Treatment of Relapsed/Refractory Multiple Myeloma
| Press Release |  |
04 Jun 2021 | Ichnos Sciences Presents Preclinical Data Confirming Potential for ISB 1342 in Relapsed/Refractory Multiple Myeloma at 2021 ASCO Annual Meeting
| Press Release |  |
27 May 2021 | May 2021 Update
| Corporate Update |  |